KELIX bio is a buy-and-build specialty generic business focused on emerging markets and designed to compete through innovation and cost leadership.
KELIX bio brings high-quality specialty products at affordable prices to populations across emerging markets who could not historically afford them.
The company’s investors currently include Development Partners International (DPI), CDC Group, the UK’s publicly owned impact investor, and the European Bank for Reconstruction and Development (EBRD).
KELIX bio takes guidance and inspiration from its core values of integrity, performance, quality, and care, to help it create value for all stakeholders, patients, healthcare professionals, payors, and ultimately its shareholders.
 KELIX  bio  serves a diverse base of clients, reaching out to governments through its participation in tenders, as well as hospitals, and partnering closely with healthcare professionals and caregivers. It differentiates itself from competitors through the uncompromising quality of its products and through its cost leadership.
KELIX bio takes pride in materially expanding the pool of cancer patients that can now have access to oncology drugs at affordable prices.

KELIX bio Malta

Org chart

Teams

Offices